07:13 AM EDT, 06/10/2024 (MT Newswires) -- Pfizer's ( PFE ) Paxlovid showed no clear benefits for those suffering from long-COVID symptoms, Stanford Medicine said in a paper published Friday.

The 155-patient study found that a 15-day regimen of the drug was safe in patients with long COVID but did not show any improvement. A five-day regimen of the drug has been shown to reduce patients' likelihood of hospitalization and death by more than 85%, according to the paper.

At 10 weeks into the trial, researchers found no statistically significant difference between patients given Paxlovid and those treated with another antiviral drug in the study's primary endpoint of a reduction in the severity of core long-COVID symptoms.

The findings were published last week in the Journal of the American Medical Association Internal Medicine.

"Paxlovid, effective in preventing severe COVID-19, didn't appear to help long-COVID patients in this single-center study," Stanford Medicine said. "But further research may show benefits with different doses or for people with specific symptoms."

Price: 28.63, Change: +0.05, Percent Change: +0.17